TP53突变状态将复杂核型骨髓增生异常综合征分为不同的预后亚组
研究分析国际MDS工作组共享的359例复杂核型(CK)MDS患者数据,55%携带TP53突变。多变量模型识别出严重贫血、NRAS突变、SF3B1突变、TP53突变、原始细胞比例升高、3q异常、9号染色体异常和7号单体为最大生存风险因素,CK-MDS的不良预后由TP53突变驱动并可结合临床与核型特征细化。
要点
- 359例CK-MDS中55%携带TP53突变,TP53突变者合并del(5q)、单体核型和高度复杂核型更常见。
- 单体核型、高度复杂核型和TP53突变各自与较短总生存相关,但单体状态在多变量模型中不显著。
- 多变量模型显示严重贫血、NRAS突变、SF3B1突变、TP53突变、原始细胞>10%、3q异常、9号染色体异常和7号单体生存风险最大。
核心结论
- CK-MDS的不良预后与其携带预后不良的TP53突变相关,并可通过结合临床和核型特征进一步细化风险分层。
研究设计与样本
- 研究为国际MDS工作组共享数据的分析,纳入359例复杂核型骨髓增生异常综合征患者。
主要发现
- TP53突变见于55%的CK-MDS患者,TP53突变者共突变基因更少,但del(5q)(p < 0.005)、单体核型(p < 0.001)和高度复杂核型即超过4个细胞遗传学异常(p < 0.001)更常见。
- 单体核型、高度复杂核型和TP53突变各自与较短总生存相关,但单体状态在多变量模型中不显著。
- 多变量生存模型识别出严重贫血(血红蛋白 < 8.0 g/dL)、NRAS突变、SF3B1突变、TP53突变、原始细胞比例升高(>10%)、3q异常、9号染色体异常和7号单体具有最大生存风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS). Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic abnormalities, which is a highly adverse prognostic marker. However, CK-MDS can carry a wide range of chromosomal abnormalities and somatic mutations. To refine risk stratification of CK-MDS patients, we examined data from 359 CK-MDS patients shared by the International Working Group for MDS. Mutations were underrepresented with the exception of TP53 mutations, identified in 55% of patients. TP53 mutated patients had even fewer co-mutated genes but were enriched for the del(5q) chromosomal abnormality (p < 0.005), monosomal karyotype (p < 0.001), and high complexity, defined as more than 4 cytogenetic abnormalities (p < 0.001). Monosomal karyotype, high complexity, and TP53 mutation were individually associated with shorter overall survival, but monosomal status was not significant in a multivariable model. Multivariable survival modeling identified severe anemia (hemoglobin < 8.0 g/dL), NRAS mutation, SF3B1 mutation, TP53 mutation, elevated blast percentage (>10%), abnormal 3q, abnormal 9, and monosomy 7 as having the greatest survival risk. The poor risk associated with CK-MDS is driven by its association with prognostically adverse TP53 mutations and can be refined by considering clinical and karyotype features.
引用
- Haase D, Stevenson KE, Neuberg D, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019. PMID: 30635634. doi:10.1038/s41375-018-0351-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。